Windtree Therapeutics (WINT) News Today → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free WINT Stock Alerts $5.03 -0.27 (-5.09%) (As of 04/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWindtree Therapeutics is dangerously low on cashbizjournals.com - April 22 at 5:05 PMmarketbeat.com - April 22 at 6:06 AMWindtree Therapeutics Announces Reverse Stock Split in Strategy to Boost Market Compliancemsn.com - April 21 at 10:45 AMWindtree Therapeutics Stock Scheduled to Reverse Split on Monday, April 22nd (NASDAQ:WINT)americanbankingnews.com - April 20 at 1:24 AMWhy Windtree Therapeutics (WINT) Stock Is Getting Hammeredmsn.com - April 18 at 6:04 PMWindtree Therapeutics Announces Reverse Stock Splitglobenewswire.com - April 18 at 8:00 AMWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updatesfinance.yahoo.com - April 17 at 10:36 AMWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updatesglobenewswire.com - April 17 at 8:00 AMWindtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financingfinanznachrichten.de - April 9 at 8:09 AMWindtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financingglobenewswire.com - April 8 at 4:48 PMWindtree Therapeutics Seeks Strategic Alternatives with Ladenburg Thalmannmsn.com - February 2 at 1:10 AMWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Researchfinance.yahoo.com - February 1 at 10:09 AMWindtree Therapeutics hires investment bank to explore M&A optionsbizjournals.com - January 31 at 1:46 PMWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternativesfinance.yahoo.com - January 31 at 1:46 PMWindtree Therapeutics – This Biotech Inks License Deal For Lead Candidatebenzinga.com - January 29 at 1:53 PMWindtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management Companyfinanznachrichten.de - January 26 at 7:18 PMWindtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Companyfinance.yahoo.com - January 26 at 7:18 PMWindtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Companybenzinga.com - January 25 at 12:19 PMWindtree Eliminates $15 Million Contingent Liability to Deerfield Management Companyfinance.yahoo.com - January 25 at 12:19 PMWindtree Therapeutics Incmoney.usnews.com - January 24 at 12:22 AMWindtree and Lee’s sign licence deal for heart failure therapymsn.com - January 18 at 3:29 PMUp To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater Chinafinance.yahoo.com - January 18 at 10:28 AMWindtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug companybizjournals.com - January 17 at 6:16 PMWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Regionfinance.yahoo.com - January 17 at 8:16 AMHold Rating on Windtree Therapeutics Pending Key Istaroxime Studiesmarkets.businessinsider.com - January 4 at 12:13 AMHC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral Recommendationmsn.com - January 3 at 7:12 PMWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activatormarkets.businessinsider.com - January 2 at 7:16 PMWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activatorfinance.yahoo.com - January 2 at 7:16 PMIstaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024finance.yahoo.com - December 19 at 12:07 PMWindtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shockfinance.yahoo.com - December 18 at 9:44 AMWindtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patentfinance.yahoo.com - November 16 at 8:08 AMWindtree TherapeuticS GAAP EPS of -$0.86msn.com - November 9 at 10:58 PMWindtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updatesfinance.yahoo.com - November 9 at 5:57 PMWindtree to Present at the Sidoti Micro Cap Conference on November 16thfinance.yahoo.com - November 8 at 10:47 AMWindtree to Present at the ThinkEquity Conference on October 19th in New York Citytmcnet.com - October 12 at 8:00 AMWindtree to Present at the ThinkEquity Conference on October 19th in New York Cityfinance.yahoo.com - October 12 at 8:00 AMWindtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17thfinance.yahoo.com - October 10 at 9:56 AMWindtree to Present at the Dawson James Small Cap Growth Conference on October 12thfinance.yahoo.com - October 3 at 10:32 AMWindtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Officemarkets.businessinsider.com - August 23 at 8:28 AMWindtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Officefinance.yahoo.com - August 23 at 8:28 AMWindtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Marketfinance.yahoo.com - August 16 at 5:43 PMHow Windtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activatorsbenzinga.com - August 15 at 5:22 PMWindtree Therapeutics (NASDAQ: WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Marketbenzinga.com - August 15 at 5:22 PMWindtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updatesfinance.yahoo.com - August 8 at 9:18 AMWindtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failurefinance.yahoo.com - July 25 at 12:52 PMThe Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Marketfinance.yahoo.com - July 18 at 12:31 PMWindtree Therapeutics – This Biotech Is Developing Drugs For Patients In Crisisbenzinga.com - July 14 at 12:05 PMMedical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change Thatfinance.yahoo.com - July 14 at 12:04 PMMedical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change Thatbenzinga.com - July 12 at 1:15 PMWindtree Therapeutics (WINT) Price Target Decreased by 47.37% to 5.10msn.com - July 7 at 12:24 AM Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address Have You Seen Elon’s New A.I. Device? (Picture Inside) (Ad)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast... This strange new device to protect us against that A.I. threat... WINT Media Mentions By Week WINT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. WINT News Sentiment▼1.000.34▲Average Medical News Sentiment WINT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. WINT Articles This Week▼11▲WINT Articles Average Week Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRZN News Today INKT News Today PLUR News Today ACHL News Today INAB News Today TARA News Today ZIVO News Today CYTH News Today EVAX News Today BCLI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:WINT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersThe Gold Grab of the CenturyColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump’s last act as President Porter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs Tesla going out of business?DTIREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
